Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study

• Published in: JGH open Vol. 8; no. 4; pp. e13068 - n/a
• Main Authors: Morita, Atsuhiro, Tamaki, Nobuharu, Kobashi, Haruhiko, Mori, Nami, Tsuji, Keiji, Takaki, Shintaro, Hasebe, Chitomi, Akahane, Takehiro, Ochi, Hironori, Mashiba, Toshie, Urawa, Naohito, Fujii, Hideki, Mitsuda, Akeri, Kondo, Masahiko, Ogawa, Chikara, Uchida, Yasushi, Narita, Ryoichi, Marusawa, Hiroyuki, Kubotsu, Yoshihito, Matsushita, Tomomichi, Shigeno, Masaya, Yoshida, Hideo, Tanaka, Katsuaki, Okamoto, Eisuke, Kasai, Toyotaka, Ishii, Toru, Okada, Kazuhiko, Kurosaki, Masayuki, Izumi, Namiki
• Format: Journal Article
• Language: English
• Published: Melbourne Wiley Publishing Asia Pty Ltd 01.04.2024; John Wiley & Sons, Inc; Wiley
• Subjects: chronic hepatitis C; cirrhosis; Cohort analysis; Females; Genotype & phenotype; glecaprevir and pibrentasvir (GLE/PIB); Hepatitis C; Liver cancer; Liver cirrhosis; Patients; Statistical analysis; treatment periods; Japan; glecaprevir and pibrentasvir (GLE/PIB); treatment periods; cirrhosis; chronic hepatitis C
• ISSN: 2397-9070; 2397-9070
• DOI: 10.1002/jgh3.13068

Background and aim In patients with chronic hepatitis C, 8 weeks of glecaprevir and pibrentasvir (GLE/PIB) treatment for chronic hepatitis (non‐cirrhosis) and 12 weeks for cirrhosis have been approved in Japan. However, whether 8 weeks of treatment for cirrhosis may reduce treatment efficacy has not been adequately investigated. Methods This prospective, nationwide, multicenter cohort study enrolled 1275 patients with chronic hepatitis C who received GLE/PIB therapy. The effect of liver fibrosis and treatment periods on the efficiency of GLE/PIB therapy was investigated. The primary endpoint was the sustained virological response (SVR) rate in patients with chronic hepatitis (non‐cirrhosis) and cirrhosis. The association between treatment periods and liver fibrosis on the SVR after 12 weeks of treatment rate was investigated. Results The SVR rates in patients with chronic hepatitis with 8 weeks of treatment, chronic hepatitis with 12 weeks of treatment, cirrhosis with 8 weeks of treatment, and cirrhosis with 12 weeks of treatment were 98.9% (800/809), 100% (87/87), 100% (166/166), and 99.1% (211/213), respectively, and were was not different among these groups (P = 0.4). Conclusion GLE/PIB therapy for chronic hepatitis C had high efficacy regardless of liver fibrosis status and treatment periods. Periods of GLE/PIB therapy could be chosen with available modalities, and high SVR rates could be achieved regardless of the decision. GLE/PIB therapy for chronic hepatitis C had high efficacy regardless of liver fibrosis status and treatment periods. Periods of GLE/PIB therapy could be chosen with available modalities, and high SVR rates could be achieved regardless of the decision.